Let's solve your problem together
Whole collection based on Evidence
News
Cybersecurity For Cardiovascular Implantable Electronic Devices: What Should You Know?
The potential for hacking cardiovascular implantable electronic devices such as pacemakers and defibrillators may be a growing problem for patients and health care providers.
Wireless communication between health care providers and patients’ devices has enhanced, so has the possibility of manipulating normal interactions such as deactivating features; delaying, interfering or interrupting communications; and altering programming.
These manipulations could be of major harm to patients and a risk to clinical care.
For example, in pacemakers, patient safety issues can come from oversensing or sudden battery depletion, the authors explain. Just like other causes of electromagnetic interference, the detection of signals of non-cardiac origin may prevent pacing, causing for prolonged periods of asystole with the risk of syncope or sudden death.
As new cyber vulnerabilities quickly emerge, the scietists note that cybersecurity needs should be addressed during product testing both pre- and post-market to ensure a safe system.
Other options to improve cybersecurity include using a protective software such as firmware, which is embedded in the hardware of devices, and remote monitoring or interrogation of all tele-monitored devices.
In addition, the authors suggest that physicians who manage cardiovascular implantable electronic devices should be aware of both documented and possible cybersecurity risks, and engage patients in conversation and shared decision-making.
Clinics and hospitals should also review security updates and keep track of any issues at hand.
While it is important to stay alert, the Council states that no enhanced monitoring or elective device replacement is necessary at this point, and there is currently no evidence that a cardiovascular implantable electronic devices can be reprogramed.
“The possible future impact of this issue is immense,” the authors conclude. “The FDA, manufacturers and professional societies like the American College of Cardiology and Heart Rhythm Society are actively participating in larger conversations regarding overall risks, and how to best protect patients and provide the most effective care.”
